NovaBay Pharmaceuticals Inc

Type: Company

Name: NovaBay Pharmaceuticals Inc

Web Address: http://www.novabaypharma.com/

First reported Jun 17 2013 - Updated Jun 17 2013 - 5 reports

NovaBay Supports Legislation to Attack Antibiotic Resistance CEO Cites Growing Crisis

(GLOBE NEWSWIRE) -- Dr. Ron Najafi, Chairman and Chief Executive Officer of NovaBay Pharmaceuticals, Inc. (NYSE:NBY) today announced NovaBay's support for legislation by U.S. Rep. Jim Matheson... ... [Published Drugs.com - Jun 17 2013]

Entities: NovaBay Pharmaceuticals Inc, Antibiotic-Resistant, Crisis, Jim Matheson

First reported Jun 11 2013 - Updated Jun 11 2013 - 5 reports

Phase II

Clinical Results From Three Auriclosene Phase 2 Trials Expected

in Second Half of This Year EMERYVILLE, Calif., June 11, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc., (NYSE:NBY), a clinical-stage biotechnology company... ... [Published Drugs.com - Jun 11 2013]

Entities: Phase II, NovaBay Pharmaceuticals Inc, Biotechnology

First reported Jun 11 2013 - Updated Jun 11 2013 - 1 reports

Seven Biotech Options That Buck Tradition: Christian Glennie

This interview was conducted by George S. Mack of The Life Sciences Report (6/6/13)Edison Investment Research assesses the value of emerging companies with a model that assumes revenues and earnings are years away. Then again, every investor does that. ... [Published Trefis - Jun 11 2013]

Entities: amitiza, Biotie Therapies Oyj, MediGene AG, Barda (Russia), Selincro

First reported Jun 06 2013 - Updated Jun 06 2013 - 1 reports

Seven Biotech Options that Buck Tradition: Christian Glennie

(Investorideas.com Newswire) Edison Investment Research assesses the value of emerging companies with a model that assumes revenues and earnings are years away. Then again, every investor does that. What's unusual is that Edison looks for tomorrow's upside ... [Published InvestorIdeas.com - Jun 06 2013]

Entities: amitiza, Biotie Therapies Oyj, Selincro, Barda (Russia)

First reported Jun 06 2013 - Updated Jun 06 2013 - 1 reports

NovaBay Pharmaceuticals Inc

RedChip Issues Research Profile on NovaBay Pharmaceuticals

(GLOBE NEWSWIRE) -- RedChip Companies, Inc., today announced it has issued a research profile on NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global, topical anti-infective ... [Published Benzinga.com - Jun 06 2013]

Entities: NovaBay Pharmaceuticals Inc, NeutroPhase, Investor Relations, Security

First reported May 28 2013 - Updated May 29 2013 - 6 reports

NovaBay Pharma inks collaboration and license pact with Virbac for animal health

NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, has entered into a collaboration and license agreement with Virbac, a global veterinary product company. Virbac exercised its March 2012 Feasibility and Option Agreement, thereby acquiring ... [Published PharmaBiz - May 29 2013]

Entities: Virbac SA, NovaBay Pharmaceuticals Inc, Animal Health, collaboration

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Investment Research Weekly Roundup including: Mwana Africa, Simba Energy and African Eagle Resources

African Eagle - LON:AFE Flash note - Dutwa project winding up 16 May 2013 African Eagle has been unable to source additional funding to develop the Dutwa nickel project. The search for a strategic partner continues, but the Dutwa project company ... [Published Proactiveinvestors United Kingdom RSS feed - May 17 2013]

Entities: Simba Energy Inc, Mwana Africa, African Eagle Resources PLC, Cytori Therapeutics Inc

First reported Apr 10 2013 - Updated Apr 10 2013 - 1 reports

NovaBay enrols first patient in BAYnovation global phase IIb trial

NovaBay Pharmaceuticals, Inc., a biotechnology company has enrolled its first patient in Brazil into its global phase IIb clinical trial, BAYnovation. The trial is investigating Auriclosene (NVC-422) Ophthalmic Solution as a treatment for adenoviral conjunctivitis, ... [Published PharmaBiz - Apr 10 2013]

Entities: NovaBay Pharmaceuticals Inc, Phase IIb, Brazil

First reported Mar 18 2013 - Updated Mar 18 2013 - 2 reports

NovaBay CEO Interviewed on RedChip Money Report on Fox Business News

- Dr. Ron Najafi Highlights Aganocide Anti-Infective Platform - - Increasing Bacterial Resistance Requires New Treatment Paradigm - EMERYVILLE, Calif., March 18, 2013 (GLOBE NEWSWIRE) -- NovaBay$ Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company ... [Published GlobeNewswire - Mar 18 2013]

Entities: NovaBay Pharmaceuticals Inc, Phase IIb, Dermatology

First reported Mar 15 2013 - Updated Mar 15 2013 - 1 reports

RedChip TV Announces Guest Lineup for This Week's "Money Report" on Fox Business News

This week's show features interviews with Dr. Ron Najafi, chairman and CEO of NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company; John Lorenz, chairman and CEO of GlyEco, Inc. (OTCQB:GLYE), a green chemistry company; and Thomas Braun, ... [Published Stockwatch - Mar 15 2013]

Entities: Investor Relations, Verisante Technology Inc, NovaBay Pharmaceuticals Inc, Jim Collins

First reported Feb 22 2013 - Updated Feb 22 2013 - 1 reports

WHO approves auriclosene as INN

Emeryville, CA—The World Health Organization has approved the international nonproprietary name (INN) ”auriclosene” (pronounced awr-rih-CLO-zeen) for NovaBay Pharmaceuticals, Inc.’s lead Aganocide compound NVC-422.NovaBay’s proprietary Aganocides are ... [Published Modern Medicine - Feb 22 2013]

Entities: NovaBay Pharmaceuticals Inc, World Health Organization, Ophthalmology, Bacteria

First reported Jan 24 2013 - Updated Jan 24 2013 - 1 reports

The Market Waits For NovaBay

ByRichard Richter: Earlier this week, highly speculative microcap biotech company NovaBay Pharmaceuticals Inc, ( NBY ) launched a new, investor-oriented mobile app in order "to more effectively communicate with our investment community" (according ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Jan 24 2013]

Entities: NovaBay Pharmaceuticals Inc, Market, Biotechnology, Allotment

Quotes

...Matheson's bill is an important contribution," Dr. Najafi said. "We've reached a critical tipping point where we must replace antibiotics, whenever possible, with safe and effective alternatives that kill bacteria without developing resistance. "

NovaBay Supports Legislation to Attack Antibiotic Resistance [Published SPi World News - Jun 17 2013]

...Dr. Ron Najafi, Chairman and CEO of NovaBay Pharmaceuticals, explained, "This is an important year for NovaBay. Each of our three auriclosene phase 2 clinical studies -- in urology, dermatology, and ophthalmology -- is expected to report da..."

Clinical Results From Three Auriclosene Phase 2 Trials Expected [Published Big News Network - Jun 11 2013]

...By tracking the size and price of each montha'a "s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin."

NBY, DGICA, STV, MHR, RPT, CFNL Are Seasonally Ripe To Go Down In the Next Five Weeks [Published TradingCharts.com - Jun 11 2013]

Jean-Pascal Marc, Corporate Product Innovation Director of Virbac commented: "We are pleased to be using our decades-strong leadership in veterinary medicine to explore the development of NovaBay's auriclosene in animal health uses. The agreement with NovaBay is in line with Virbac's strategy of seeking innovative products which have the potential to create value and adapted to animal health market evolution." NovaBay Pharmaceuticals is a biotechnology company focused on addressing the large unmet therapeutic needs of the global, topical anti-infective market...

NovaBay Pharmaceuticals and Virbac Enter Into a Collaboration and License Agreement for Animal He ... [Published Street Insider - May 28 2013]

More Content

sort by: Date \| Relevance
NovaBay Supports Legislation to Attack Antibiot... [Published Drugs.com - Jun 17 2013]
NovaBay Pharmaceuticals, Inc. (NBY) Supports Le... [Published BioSpace - Jun 17 2013]
NovaBay Supports Legislation to Attack Antibiot... [Published Reuters - Jun 17 2013]
NovaBay Supports Legislation to Attack Antibiot... [Published SPi World News - Jun 17 2013]
NovaBay Supports Legislation to Attack Antibiot... [Published Benzinga.com - Jun 17 2013]
ENZ Fattens Purse, SLXP, MNKD Hit Highs, QCOR's... [Published RTTNews.com - Jun 12 2013]
Clinical Results From Three Auriclosene Phase 2... [Published Drugs.com - Jun 11 2013]
Clinical Results From Three Auriclosene Phase 2... [Published Big News Network - Jun 11 2013]
NovaBay: Upcoming Auriclosene Data Could Be A C... [Published Seeking Alpha - Jun 11 2013]
Seven Biotech Options That Buck Tradition: Chri... [Published Trefis - Jun 11 2013]
NOVABAY PHARMACEUTICALS, INC. : NovaBay Pharmac... [Published 4 Traders - Jun 11 2013]
NovaBay Pharmaceuticals Mid-Year Clinical Update [Published GlobeNewswire: Acquisitions News - Jun 11 2013]
NovaBay Pharmaceuticals Mid-Year Clinical Update [Published Morningstar.com - Jun 11 2013]
NBY, DGICA, STV, MHR, RPT, CFNL Are Seasonally ... [Published TradingCharts.com - Jun 11 2013]
SmithOnStocks Opines: June 9, 2013 [Published Seeking Alpha - Jun 10 2013]
Seven Biotech Options that Buck Tradition: Chri... [Published InvestorIdeas.com - Jun 06 2013]
Viral Conjunctivitis - Pipeline Review, H1 2013... [Published Individual.com - Jun 06 2013]
RedChip Issues Research Profile on NovaBay Phar... [Published GlobeNewswire: Advertising News - Jun 06 2013]
RedChip Issues Research Profile on NovaBay Phar... [Published Benzinga.com - Jun 06 2013]
NovaBay Pharma inks collaboration and license p... [Published PharmaBiz - May 29 2013]
NovaBay Pharmaceuticals, Inc. and Virbac Corpor... [Published BioSpace - May 28 2013]
Virbac Buys Rights to Develop NovaBay's Auriclo... [Published Genetic Engineering News - May 28 2013]
NovaBay Pharma, Virbac Reach Collaboration And ... [Published RTTNews.com - May 28 2013]
NovaBay Pharmaceuticals and Virbac Enter Into a... [Published Reuters - May 28 2013]
NovaBay Pharmaceuticals and Virbac Enter Into a... [Published Street Insider - May 28 2013]
NovaBay Pharmaceuticals and Virbac Enter Into a... [Published GlobeNewswire: Acquisitions News - May 28 2013]
Investment Research Weekly Roundup including: M... [Published Proactiveinvestors United Kingdom RSS feed - May 17 2013]
NovaBay Pharmaceuticals Reports First Quarter F... [Published GlobeNewswire: Acquisitions News - May 02 2013]
NovaBay enrols first patient in BAYnovation glo... [Published PharmaBiz - Apr 10 2013]
NovaBay Global Ophthalmology Study Enrolls Firs... [Published GlobeNewswire: Advertising News - Apr 08 2013]

sort by: Date \| Relevance
Frontrunning: March 14 [Published Zero Hedge - Mar 14 2013] Dimon’s ‘Harpooned’ Whale Resurfaces With Senate Findings ( BBG ) Greece and lenders fall out over firings ( FT ) - as predicted 48 hours ago Dallas Fed Cap Seen Shrinking U.S. Banking Units by Half ( BBG ) - which is why it will never happen Xi elected ...
UPS Gets an Outperform and 4 Analyst Notes to Know [Published Wall St. Cheat Sheet - Mar 06 2013] Stock upgrades and downgrades are a controversial part of Wall Street. Despite regulations, many banks and firms still have a positive bias toward current clients and companies desired as future clients. In addition, Wall Street analysts are straight-up ...